MARKHAM, ON--(Marketwire - December 15, 2010) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce the acquisition of FORTEX Rubbing Oil® from Actium Pharmaceuticals, Inc. The acquisition now provides Axxess Pharma quick entry into the $35 billion arthritis market. FORTEX is currently sold in 20 countries worldwide. Under the terms of the acquisition, Axxess Pharma now has exclusive distribution rights throughout Canada.
FORTEX is a topical medication requested by physicians on a daily basis. The medication provides rapid and lasting relief of pain associated with musculoskeletal conditions, such as arthritis and soft tissue injuries. Once applied to the skin, FORTEX is readily absorbed directly down to the site of pain. Topical medications such as FORTEX are rapidly expanding due to patients no longer choosing to experience painful side effects caused by their oral pain medication. These side effects are well documented by medical professionals and patients and range from mild, severe and sometimes fatal reactions.
Locally acting topical medications such as FORTEX have the potential to exhibit a safer side effect profile as they deliver the drug directly to the pain site through the skin, resulting in lower levels of the active ingredient entering the blood stream compared to oral medications. Axxess Pharma anticipates strong sales due to demand in the Canadian market.
According to the Arthritis Society of Canada, over 4 million Canadians are diagnosed with arthritis resulting in over 8.8 million physician visits per year for arthritis and related conditions. These numbers are anticipated to continue to increase due to the aging population and obesity.
"I am pleased with Axxess Pharma's business relationship, and the prospects it brings for FORTEX in the Canadian market. FORTEX possesses a unique position for this market. The product works and allows clinicians and patients a cost-effective way to manage musculoskeletal pain and discomfort. This is accomplished by enabling the replacing, decreasing, or adding to, oral-NSAID therapy, which is costly and comes with risks," said Michel Lockhart, representative for Actium Pharmaceuticals.
For more information, please contact Investor Relations at (973) 351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.